Adjuvant chemotherapy in stage III colon cancer: Guideline implementation, patterns of use and outcomes in daily practice in The Netherlands

References

• Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74–108.
   PubMed Web of Science ®Google Scholar
• Obrand DI, Gordon PH. Incidence and patterns of recurrence following curative resection for colorectal carcinoma. Dis Colon Rectum 1997;40:15–24.
   PubMed Web of Science ®Google Scholar
• Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ, . Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990;322:352–8.
   PubMed Web of Science ®Google Scholar
• Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, . Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343–51.
   PubMed Web of Science ®Google Scholar
• Twelves C, Wong A, Nowacki MP, Abt M, Burris H, , 3rdCarrato A, . Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005;352:2696–704.
   PubMed Web of Science ®Google Scholar
• Punt CJ. New options and old dilemmas in the treatment of patients with advanced colorectal cancer. Ann Oncol 2004;15:1453–9.
   PubMed Web of Science ®Google Scholar
• Shields AF, Zalupski MM, Marshall JL, Meropol NJ. Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine: A phase II trial. Cancer 2004;100:531–7.
   PubMed Web of Science ®Google Scholar
• Cassidy J, Tabernero J, Twelves C, Brunet R, Butts C, Conroy T, . XELOX (capecitabine plus oxaliplatin]: Active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004;22:2084–91.
   PubMed Web of Science ®Google Scholar
• Kuebler JP, Wieand HS, O’Connell MJ, Smith RE, Colangelo LH, Yothers G, . Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: Results from NSABP C-07. J Clin Oncol 2007;25:2198–204.
   PubMed Web of Science ®Google Scholar
• Schmoll HJ, Cartwright T, Tabernero J, Nowacki MP, Figer A, Maroun J, . Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: A planned safety analysis in 1,864 patients. J Clin Oncol 2007;25: 102–9.
   PubMed Web of Science ®Google Scholar
• Andre T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, . Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC Trial. J Clin Oncol 2009;27:3109–16.
   PubMed Web of Science ®Google Scholar
• Labianca R, Nordlinger B, Beretta GD, Brouquet A, Cervantes A, ESMO Guidelines Working Group. Primary colon cancer: ESMO Clinical Practice Guidelines for diagnosis, adjuvant treatment and follow-up. Ann Oncol 2010;21(Suppl 5): v70–7.
   Google Scholar
• Rothwell PM. External validity of randomised controlled trials: “to whom do the results of this trial apply?” Lancet 2005;365:82–93.
   PubMed Web of Science ®Google Scholar
• Silverman SL. From randomized controlled trials to observational studies. Am J Med 2009;122:114–20.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987;40:373–83.
   PubMedGoogle Scholar
• Lemmens VE, van Halteren AH, Janssen-Heijnen ML, Vreugdenhil G, Repelaer van Driel OJ, Coebergh JW. Adjuvant treatment for elderly patients with stage III colon cancer in the southern Netherlands is affected by socioeconomic status, gender, and comorbidity. Ann Oncol 2005;16:767–72.
   PubMed Web of Science ®Google Scholar
• Kahn KL, Adams JL, Weeks JC, Chrischilles EA, Schrag D, Ayanian JZ, . Adjuvant chemotherapy use and adverse events among older patients with stage III colon cancer. JAMA 2010;303:1037–45.
   PubMed Web of Science ®Google Scholar
• Goldberg RM, Tabah-Fisch I, Bleiberg H, de Gramont A, Tournigand C, Andre T, . Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 2006;24:4085–91.
   PubMed Web of Science ®Google Scholar
• McCleary JN, Meyerhardt J, Green E, Yothers G, de Gramont A, Van Cutsem E, . Impact of older age on the efficacy of newer adjuvant therapies in > 12,500 patients (pts) with stage II/III colon cancer: Findings from the ACCENT Database (abstract). J Clin Oncol 2009;27(170s).
   Google Scholar
• Haller DG, Cassidy J, Tabernero J, Maroun JA, De Braud FG, Price TJ, . Efficacy findings from a randomized phase III trial of capecitabine plus oxaliplatin verus bolus 5-FU/LV for stage III colon cancer (NO16968): No impact of age on disease-free survival (DFS). (abstract). Presented at the 2010 ASCO gastrointestinal cancers Symposium, Orlando, FL, January 22. 2010.
   Google Scholar
• Etzioni DA, El-Khoueiry AB, Beart RW, Jr. Rates and predictors of chemotherapy use for stage III colon cancer: A systematic review. Cancer 2008;113:3279–89.
   PubMed Web of Science ®Google Scholar
• van Steenbergen LN, Rutten HJ, Creemers GJ, Pruijt JF, Coebergh JW, Lemmens VE. Large age and hospital-dependent variation in administration of adjuvant chemotherapy for stage III colon cancer in southern Netherlands. Ann Oncol 2010;21:1273–8.
   PubMed Web of Science ®Google Scholar
• Arkenau HT, Arnold D, Cassidy J, Diaz-Rubio E, Douillard JY, Hochster H, . Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: A pooled analysis of randomized trials. J Clin Oncol 2008;26:5910–7.
   PubMed Web of Science ®Google Scholar
• Haller D, Tabernero J, Maroun J, De Braud F, Price T, Van Cutsem E, . First efficacy findings from a randomized phase III trial of capecitabine + oxaliplatin vs. bolus 5-FU/LV for stage III colon cancer (NO16968/XELODA study). Presented at the joint ECCO/ESMO multidisciplinary congress, (abstr 5LBA), Berlin, 20–24 September, 2009.
   Google Scholar
• Mol L, Punt CJA, van Gils CWM, Ottevanger PB, Koopman M. Trial participation in a multicentre phase III trial (CAIRO) in advanced colorectal cancer patients in The Netherlands, and a comparison of outcome between trial and non-trial patients. (abstract 581PD). Presented at the 35th ESMO Congress Milan, Italy 8–12 October, 2010.
   Google Scholar